<DOC>
	<DOCNO>NCT00397553</DOCNO>
	<brief_summary>To provide local data efficacy safety insulin glulisine patient Type 1 Diabetes Mellitus receive insulin glargine basic insulin therapy</brief_summary>
	<brief_title>Insulin Glulisine , Diabetes Mellitus Type 1</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus , Type 1 HbA1c 6.511.0 % BMI &lt; 35 kg/mÂ² Diabetes mellitus , Type 2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>